We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
-21.47%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$9.8M
AUM Growth
-$14.4M
Cap. Flow
-$9.62M
Cap. Flow %
-98.22%
Top 10 Hldgs %
100%
Holding
2
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.62M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.15M 93.42%
1,347,829
-1,350,000
-50% -$9.62M
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$645K 6.58%
2,790,964

Similar funds

TRV GP II's Q1 2022 Portfolio in Review

As of Q1 2022, TRV GP II held 2 positions worth $9.8M, down 59% from $24.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $9.62M in Q1 2022, reducing 1 holding. Its largest reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $9.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q1 2022 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $9.62M.
  • TRV GP II's ten largest holdings make up 100% of its $9.8M portfolio in Q1 2022.
  • TRV GP II opened 0 new positions and closed 0 in Q1 2022.
  • TRV GP II's portfolio value fell 59% quarter-over-quarter to $9.8M.

Based on TRV GP II's 13F filing for Q1 2022, filed 10 May 2022.